Dermatitis News

The effect of the COVID-19 pandemic has been felt in every aspect of life in 2020, and that includes the dermatology world.

The FDA approved drugs and products for many dermatological diseases and conditions in 2020. Here are some of the top-read articles on Healio regarding this year’s dermatology FDA approvals.

The marketing authorization for Dupixent has been extended in the European Union to include children ages 6 to 11 years with severe atopic dermatitis, Regeneron and Sanofi announced in a press release.

Patients with moderate to severe atopic dermatitis had a greater improvement with abrocitinib 100 mg or 200 mg than with placebo, according to pooled results presented at the European Academy of Dermatology and Venereology virtual congress.

Researchers discussed racial and ethnic disparities in various aspects of allergy at this year’s virtual meeting of the American College of Allergy, Asthma and Immunology.

Patients with skin allergies who wear certain types of face masks may experience adverse events, according to a presenter at this year’s virtual American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

Aloe vera cream showed success in treating dermatitis in health care workers during the COVID-19 pandemic, according to a poster presented at the European Academy of Dermatology and Venereology virtual congress.

Two phase 3 clinical trials of upadacitinib showed positive results in adolescent and adult patients with atopic dermatitis, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.

Arcutis Biotherapeutics has completed enrollment in a phase 1/2b study of ARQ-252, a JAK1 inhibitor, for the treatment of chronic hand eczema, according to a press release.

Eczema affects 10% of people in the United States, more than 31 million individuals, according to the National Eczema Association.